Quanterix (QTRX) FDA Approvals $3.07 -0.05 (-1.60%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$3.06 -0.01 (-0.23%) As of 09/18/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Quanterix's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Quanterix (QTRX). Over the past two years, Quanterix has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Simoa. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Simoa p-Tau 217 FDA Regulatory Events Simoa p-Tau 217 is a drug developed by Quanterix for the following indication: Redefining Alzheimer's Disease Neuropathology Prevalence. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Publication - December 22,2025Publication Drug: Simoa p-Tau 217Announced Date: December 22, 2025Indication: Redefining Alzheimer's Disease Neuropathology PrevalenceAnnouncementQuanterix Corporation announced publication of a landmark study in the prestigious journal Nature.AI SummaryQuanterix Corporation announced publication of a landmark study in Nature that used its ultra‑sensitive Simoa p‑Tau 217 (phosphorylated tau at threonine 217) research assay to perform the largest population‑based assessment of Alzheimer’s disease neuropathology to date. Researchers analyzed more than 11,000 Norwegian adults aged 58 and older and found AD neuropathological change (ADNC) rises sharply with age — about 10% in ages 58–69.9 and 64.9% in those over 90. Among people 70 and older, 30.4% showed ADNC: 11.4% preclinical AD, 10.8% prodromal AD, and 7.4% AD dementia. The study also estimates roughly 10% of the 70+ population meet current treatment eligibility and links AD pathology to sex, APOE genotype, and education. The findings relied on a validated commercial p‑Tau 217 kit (ALZpath p‑Tau‑217 Advantage PLUS) run on a fully automated HD‑X analyzer. Quanterix says its Simoa platform enabled scalable, sensitive blood measurements that make population‑level screening and planning for treatments and trials more feasible.Read Announcement Quanterix FDA Events - Frequently Asked Questions Has Quanterix received FDA approval? As of now, Quanterix (QTRX) has not received any FDA approvals for its therapy in the last two years. What drugs has Quanterix submitted to the FDA? In the past two years, Quanterix (QTRX) has reported FDA regulatory activity for Simoa p-Tau 217. What is the most recent FDA event for Quanterix? The most recent FDA-related event for Quanterix occurred on December 22, 2025, involving Simoa p-Tau 217. The update was categorized as "Publication," with the company reporting: "Quanterix Corporation announced publication of a landmark study in the prestigious journal Nature." What conditions do Quanterix's current drugs treat? Currently, Quanterix has one therapy (Simoa p-Tau 217) targeting the following condition: Redefining Alzheimer's Disease Neuropathology Prevalence. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events AbCellera Biologics FDA EventsAquestive Therapeutics FDA EventsHemab Therapeutics FDA EventsAdherex Technologies FDA EventsMIRA Pharmaceuticals FDA EventsNeuroOne Medical Technologies FDA EventsQuince Therapeutics FDA EventsSol-Gel Technologies FDA EventsAbbVie FDA EventsBristol Myers Squibb FDA EventsNuvation Bio FDA EventsAbeona Therapeutics FDA EventsArtelo Biosciences FDA EventsBiogen FDA EventsFate Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies VivoSim Labs FDA Events Agilent Technologies FDA Events Revvity FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:QTRX last updated on 12/22/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | Sponsored“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quanterix Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Quanterix With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Publication - December 22,2025Publication Drug: Simoa p-Tau 217Announced Date: December 22, 2025Indication: Redefining Alzheimer's Disease Neuropathology PrevalenceAnnouncementQuanterix Corporation announced publication of a landmark study in the prestigious journal Nature.AI SummaryQuanterix Corporation announced publication of a landmark study in Nature that used its ultra‑sensitive Simoa p‑Tau 217 (phosphorylated tau at threonine 217) research assay to perform the largest population‑based assessment of Alzheimer’s disease neuropathology to date. Researchers analyzed more than 11,000 Norwegian adults aged 58 and older and found AD neuropathological change (ADNC) rises sharply with age — about 10% in ages 58–69.9 and 64.9% in those over 90. Among people 70 and older, 30.4% showed ADNC: 11.4% preclinical AD, 10.8% prodromal AD, and 7.4% AD dementia. The study also estimates roughly 10% of the 70+ population meet current treatment eligibility and links AD pathology to sex, APOE genotype, and education. The findings relied on a validated commercial p‑Tau 217 kit (ALZpath p‑Tau‑217 Advantage PLUS) run on a fully automated HD‑X analyzer. Quanterix says its Simoa platform enabled scalable, sensitive blood measurements that make population‑level screening and planning for treatments and trials more feasible.Read Announcement
